Introduction
Series of fusion proteins involving Tel, a member of the Ets transcription factor family, and receptor or nonreceptor tyrosine kinases have been associated to human leukaemias (Golub et al., 1994; Papadopoulos et al., 1995; Lacronique et al., 1997; Knezevich et al., 1998; Cazzaniga et al., 1999; Kuno et al., 2001) . The Tel-Jak2 and Tel-Abl fusions have been reported in T-and pre-B cell acute lymphoblastic leukaemias (ALL) (Papadopoulos et al., 1995; Lacronique et al., 1997; Peeters et al., 1997; Van Limbergen et al., 2001) and in various chronic myelogenous leukaemias (CML) (Peeters et al., 1997; Van Limbergen et al., 2001; Keung et al., 2002) . These proteins exhibit a constitutive kinase activity, are constitutively tyrosine phosphorylated in vivo and harbour transforming capacities in haematopoietic cell lines and mouse models (Golub et al., 1996; Lacronique et al., 2000) . Bone marrow transplantations of Tel-Abland Tel-Jak2-transduced cells into irradiated mice induce the development of a CML-like leukaemia (Million et al., 2002) and a rapid and fatal myelo-and lymphoproliferative disease respectively (Schwaller et al., 1998) . Transgenic mouse models have also illustrated the leukaemogenic properties of Tel-Jak2 in the B-and T-cell lineages (Carron et al., 2000; Dos Santos and Ghysdael, 2005) . Expression of Tel-Abl and Tel-Jak2 in haematopoietic cells results in the constitutive activation of effectors and/or pathways associated to cellular growth and survival, in particular the two adapters Gab2 and Shc, the transcription factors Stat3 and Stat5 and effectors of the NF-kB, PI3-K/Akt and Ras/Erk1/2 pathways (Voss et al., 2000; Santos et al., 2001; Ho et al., 2002; Spiekermann et al., 2002; Malinge et al., 2006) . Tel-Jak2 also activates effectors of the SAPK/JNK and p38 pathways (Ho et al., 2002) . Activation of the PI3-K/Akt and Ras/Erk1/2 signalling is partly mediated by the binding of the Grb2-Sos complex to a phosphorylated tyrosine residue (Y 314 ) present in the Tel moiety of the fusions. Following Grb2 binding, recruitment and activation of Gab2 by the oncogenes allows in turn the recruitment of the PI3-K kinase and SHP-2 phosphatase, leading to the activation of their downstream effectors Akt and Erk1/2. A TelAbl mutant lacking the Y 314 residue exhibited decreased Gab2 activation, impaired Akt and Erk1/2 phosphorylation and attenuated the induction of a CML-like disease in mice (Million et al., 2004) . Introduction of a similar substitution in the Tel-Jak2 protein fails to fully abolish the activation of the Ras/MapK pathway, arguing for alternative mechanisms of activation. In keeping, binding sites for Shc and Ship1 have been identified in Tel-Jak2 and expression of Tel-Jak2 in Ba/F3 cells results in the constitutive phosphorylation of Shc and SHP-1, recruitment of Grb2 to Tel-Jak2 and consequently activation of the Ras/MapK pathway (Ho et al., 2002) .
It remains unclear whether Tel-Jak2 and Tel-Abl fusions may activate other nonreceptor tyrosine kinases that may participate to their leukaemogenic activity. The CML-associated oncoprotein Bcr-Abl, activates members of Fps/Fes and Src families (Ernst et al., 1994; Danhauser-Riedl et al., 1996) and part of its oncogenic activity in haematopoietic cells is mediated by Src kinases (Lionberger et al., 2000; Klejman et al., 2002; Hu et al., 2004) , In particular, Hck is responsible for the phosphorylation of a critical Y 177 residue present in the fusion and associated to the recruitment of the Grb2-Sos complex and further induction of the Ras/ MapK pathway (Warmuth et al., 1997) . We therefore investigated whether Src tyrosine kinases may be required for the Tel-Abl-and Tel-Jak2-mediated transforming properties. By using the Src inhibitors PP1 and PP2, we demonstrated herein that inhibition of Src activities completely suppressed Tel-Abl proliferative signals in the IL-3-dependent lymphoid Ba/F3 cells but had no effect on Tel-Jak2 signalling. We showed that Hck is heavily phosphorylated in Tel-Abl-expressing Ba/F3 cells on the Y 411 residue known to play a critical role in Hck activity. Inhibition of Tel-Abl tyrosine kinase activity by imatinib mesylate/STI 571 blocks the phosphorylation of Hck, suggesting that this Src kinase is a downstream effector of Tel-Abl activity. We also found that expression of a kinase inactive Hck mutant inhibits the cellular growth and the phosphorylation of Akt and Erk1/2. These results indicate that Hck is involved in the Tel-Abl-mediated oncogenic signalling but dispensable for the transforming properties of Tel-Jak2.
Results
The Src kinase Hck is (hyper)phosphorylated in Tel-Abl-expressing cells To evaluate the involvement of the Src kinases in the transforming properties of Tel-Abl and Tel-Jak2 fusion proteins, we first analysed the levels of Src kinase activities in Ba/F3 cells stably expressing the two oncoproteins . We first compared patterns of phosphotyrosine proteins in these transformed cells and in parental Ba/F3 cells by Western blot using an antiphosphotyrosine antibody (4G10) (Figure 1 ). Prominent accumulations of phosphotyrosine proteins, whose molecular weights ranged from 50 to 60 kDa, were evidenced in Tel-Abl-expressing cell lysates. Among the Src kinase family members, Hck and Lyn are specifically associated with the leukaemogenic activity of Bcr-Abl and constitutively activated in haematopoietic cells transformed by this oncoprotein (Lionberger et al., 2000; Klejman et al., 2002; Hu et al., 2004) . To analyse whether Hck and Lyn activities may be affected in Tel-Abl-expressing Ba/F3 cells compared to parental or Tel-Jak2-expressing cells, cell lysates were incubated with antiphospho-Hck, antiphospho-Lyn and antiphospho-Src antibodies, which recognize the active forms of these kinases. Results clearly showed that Hck (p61Hck and p59Hck) is strongly phosphorylated in Tel-Abl-but not in Tel-Jak2-expressing cells. In contrast, the phosphorylated state of Lyn and c-Src was found similar in all samples, suggesting that Lyn and c-Src activities are not affected by the expression of Tel-Abl.
The Src kinase inhibitors PP1 and PP2 suppress the growth and survival of Ba/F3 cells transformed by Tel-Abl but have no effect on Tel-Jak2-expressing cells To evaluate the role of Hck, Ba/F3 cells expressing TelAbl or Tel-Jak2 were treated with two concentrations of the pyrazolo-pyrimidine Src kinase inhibitors PP1 and PP2. PP2 was initially described as a potent inhibitor of p56
Lck , p59 Fyn and p59/61 Hck while PP1 was reported to be selective for Fyn and Lck over other members of the Src kinases family (Hanke et al., 1996) . Incubation with PP2 and, to a lesser extent, with PP1 resulted in a dosedependent inhibition of Tel-Abl-expressing cells growth while Ba/F3 cells expressing Tel-Jak2 remained unaffected ( Figure 2a) . As a control, treatment of the two cell lines with PP3, an inactive analogue of PP2, showed no effect on cellular proliferation. Cells treated with PP2 were then stained by AnnexinV/propidium iodide (PI) to estimate the percentage of apoptosis in these cultures ( Figure 2b ). While almost negligible on 
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Tel-Jak2-expressing cells viability, PP2 treatment was shown to induce a strong increase in apoptotic cells number in the Tel-Abl-Ba/F3 cell line 24 h after addition of the compound. In addition, we also observed that PP2 treatment induced a G1 arrest in the cell cycle (data not shown). Taken together, these data reveal the requirement of Src kinase activity for the Tel-Ablmediated growth signaling.
PP2 inhibits Stat5, Erk1/2 and Akt activation in Tel-Abl-expressing cells
We next examined the contribution of Src kinases activities on the phosphorylated state of some effectors of growth and survival pathways like Stat-5, Akt and Erk1/2 (Supplementary Figure 1) . As shown in Figure 3a , Tel-Abl and Tel-Jak2 induce the phosphorylation of these proteins when compared to IL-3-starved Ba/F3 cells. These data are consistent with previously published works Santos et al., 2001; Spiekermann et al., 2002) . Treatment of Tel-Ablexpressing Ba/F3 cells with 10 mM of PP2 and, to a lesser extent with PP1, induced a strong decrease in the accumulation of phosphorylated Stat5, Akt and Erk1/2 species, while not in the Tel-Jak2 Ba/F3 cellular context (Figure 3b ). Reprobing the membranes with antibodies raised against these proteins confirmed the absence of PP1 and PP2 impacts on protein expressions.
The Src kinase inhibitors PP2 and SU6656 inhibit Tel-Abl activity The inhibitory effect of PP1 and PP2 on Src and Hck phosphorylation was confirmed in the two cell lines by Western blot using antiphospho-Src and antiphosphoHck antibodies (Figure 4a ). We also determined the effect of PP2 on Tel-Jak2 and Tel-Abl activities by Western blot analysis with anti P-Y 1007 -Jak2 and anti P-Y 245 -Abl, two tyrosine residues critical for the activity of both kinases and observed that PP2 inhibits Tel-Abl but not Tel-Jak2 phosphorylation. We also used the Src kinase inhibitor SU6656 which was previously shown to be more specific (Blake et al., 2000) . Treatment of TelAbl-expressing Ba/F3 cells with SU6656 induced growth arrest ( Figure 4b ) and inhibited the phosphorylation of Tel-Abl, Hck and c-Src kinases (Figure 4c ) thereby mimicking the effects of PP2.
Imatinib mesylate suppresses Hck, Stat5, Akt, Erk1/2 phosphorylations As the Src inhibitors PP2 and SU6656 affected the phosphorylation of Tel-Abl, we therefore determined Tel-Abl induces oncogenic signalling via Hck C Pecquet et al whether Tel-Abl targets Hck by using the Abl kinase inhibitor imatinib mesylate (STI-571, Gleevec) (Schindler et al., 2000) . Effects of imatinib mesylate on the Tel-Abl activity based on Western blot and biological analysis were determined ( Figure 5) . A complete inhibition of cell growth was already observed with 1 mM of inhibitor, a concentration needed to inhibit TelAbl activity (Figure 5a and b) . Inhibition of Hck was also observed after treatment with 1 mM of inhibitor indicating that phosphorylation of Hck is dependent on the tyrosine kinase activity of Tel-Abl (Figure 5b ). As expected, the phosphorylations of Stat5, Akt and Erk1/2 were completely suppressed after imatinib mesylate treatment. To determine whether Tel-Abl interacts with Hck in Ba/F3 cells, Tel-Abl was immunoprecipitated from Tel-Abl-expressing cell lysates and the presence of Hck was assessed by immunoblotting with antiphosphotyrosine (4G10) and anti-Hck antibodies. As shown Figure 5c , Hck was found associated with Tel-Abl in Ba/ F3 cells. Collectively, these data indicate that Hck is a downstream signalling effector of Tel-Abl.
Hck is required for Tel-Abl-induced cell growth To evaluate the role of Hck in Tel-Abl-induced mitogenic and antiapoptotic signals, we transiently expressed a Flag-tagged kinase inactive form of Hck (Hck K269E, Hck KE), its wild-type counterpart (Hck WT) or the empty vector (mock) and we measured proliferation rates and viability of the cells (Figure 6 ). We used a bicistronic expression vector allowing the coexpression of both the kinase and the hrGFP indicator (pIREShrGFP) to sort by flow cytometry and analyse 24 h post-transfection the behaviour of green fluorescent protein (GFP)-expressing cells only. In these experiments, a Flag-tagged kinase inactive form of Lyn (Lyn K275R, Lyn KR) and the WT kinase (Lyn WT) were used as controls. Rates of growth of GFPpositive cells were determined in a time course experiment using Trypan Blue dye exclusion method. As shown Figure 6 , expression of the Hck KE mutant but not of Hck WT or Lyn KR induced the Tel-Abl Ba/F3 cells growth inhibition, while Tel-Jak2-expressing cells remained insensitive. These data indicate that Hck but not Lyn activity is required for Tel-Abl-induced cell growth.
Hck is required for Tel-Abl-induced Akt and Erk1/2 phosphorylation The phosphorylation states of Akt, Stat5 and Erk1/2 were assessed by Western blot in lysates of Tel-Abl-and Tel-Jak2-expressing cells transiently transfected with the above Hck expression vectors (Figure 7) . Interestingly, we observed the disappearance of phosphorylated Akt and Erk1/2 proteins while not of phosphotyrosine Stat-5 suggesting that Hck is required in the Tel-Abl-induced activation of PI3-K/Akt and the Ras/Erks pathways.
Discussion
The Src family of tyrosine kinases consists of eight members (Src, Lyn, Lck, Fyn, Yes, Hck, Blk, Fgr) implicated in a wide variety of intracellular signalling pathways associated with cell growth, differentiation, cell shape, migration and survival as in development of cancer (Tatosyan and Mizenina, 2000) . A number of human primary tumours and tumour-derived cell lines including leukaemias possess elevated Src kinase activities (Rosen et al., 1986; Ottenhoff-Kalff et al., 1992; Talamonti et al., 1993; Mao et al., 1997; Donato et al., 2003) . For instance, Lyn and Hck have been implicated in the oncogenic activity of Bcr-Abl in haematopoietic cells (Danhauser-Riedl et al., 1996; Hu, Nature genetics, 2004) and with the use of dominant-negative src mutants or pharmacological inhibitors have confirmed that these two kinases contribute to the Bcr-Abl-induced Tel-Abl induces oncogenic signalling via Hck C Pecquet et al mitogenic and antiapoptotic signals (Lionberger et al., 2000; Wilson et al., 2002) . Here, we showed that Src kinases, and primarily Hck, is also a target of the oncogenic Tel-Abl fusion protein. Hck was found strongly phosphorylated on Y 411 residue in Tel-Ablexpressing Ba/F3 cells and treatment of the cells with imatinib mesylate, which suppresses Tel-Abl activity, inhibits Hck phosphorylation indicating that Hck is directly activated by Tel-Abl. Hck binds to four independent regions of Bcr-Abl: one region present in the Bcr portion of the fusion and three regions comprising the SH2 and SH3 domains, the kinase domain and the carboxy-terminal region of Abl Stanglmaier et al., 2003) . As the last three regions are present in the Tel-Abl fusion it is likely that Hck also binds to Tel-Abl through same domains. Tel-Abl induces oncogenic signalling via Hck C Pecquet et al Bcr-Abl-transformed haematopoietic cells. Interestingly, this interaction does not require the phosphorylation of the partners (Klejman et al., 2002) and our unpublished data also argue for a constitutive Stat5/Hck interaction in Ba/F3 cells expressing Tel-Abl that does not require the phosphorylation of Stat5 or Hck. However, since treatment with imatinib mesylate or PP2 which has been reported to inhibit also Bcr-Abl (Tatton et al., 2003; Warmuth et al., 2003) and herein Tel-Abl, suppresses Stat5 phosphorylation, Tel-Abl itself or another Src kinase may activate these factors. Although the Lyn kinase was shown to physically interact with and activate Stat5 factors (Danhauser-Riedl et al., 1996; Chin et al., 1998; Tilbrook et al., 2001) , the absence of any effect of the dominant-negative form of the kinase on Stat5 phosphorylation in Tel-Abl-expressing cells do not argue for a role of Lyn in this process (data not shown).
Tel-Abl induces a CML-like disease that is very similar to that induced by Bcr-Abl, but with a different latency (Million et al., 2002) . The Src kinases Lyn, Hck and Fgr have been demonstrated to be required for the induction of B-ALL but are dispensable for a CML-like disease (Hu et al., 2004) . The role of the Src kinases in the leukaemogenic potential of Tel-Abl remains therefore questionable. However, the situation may be different in the development of CML in human because Bcr-Abl-expressing cell lines or CD34 þ from CML patients resistant or not to imatinib mesylate treatment are sensitive to Src inhibitors or to downregulation of Src expression (Donato et al., 2003; Dai et al., 2004) . Our results support the use of Src inhibitors in the treatment of leukaemia associated with oncogenic activation of c-Abl.
Materials and methods

Cell culture and reagents
The parental Ba/F3 cells were grown in Rosewell's Park Memorial Institute media (RPMI) 1640 medium with 10% foetal calf serum and 4% WEHI conditioned medium (WCM) as a source of IL-3. Stimulation experiments were performed with recombinant murine IL-3 (Valbiotech, Paris, France) Ba/F3 cells expressing Tel-Jak2 and Tel-Abl fusions have been described elsewhere .
Imatinib mesylate (Gleevec, STI-571) was a generous gift of Novartis Pharma AG, Basel, Switzerland. The pyrazolopyrimidine Src inhibitors PP1 and PP2, the inactive analogue PP3 and SU6656 were purchased from Calbiochem-Novabiochem Co. (San Diego, CA, USA). Tel-Abl induces oncogenic signalling via Hck C Pecquet et al
Plasmids and transfections
LynWT, LynK275R, HckWT and HckK269E cDNAs which have been described elsewhere (Briggs et al., 1995; Omura et al., 2002) were amplified by polymerase chain reaction (PCR) reaction and subcloned at XhoI and EcoRI sites of the pIRES-hrGFP-1a vector (Stratagene, La Jolla, CA, USA). For transient transfections assays, cells were electroporated (300 V, 960 mF) with the different constructs or the empty vector (40 mg). Transfected cells were expanded for 24 h in medium and the (GFP) þ cells were sorted by flow cytometry (Elite, Becton-Dickinson). Proliferation and viability were next examined by counting viable cells using the Trypan Blue dye exclusion method.
Apoptosis studies
Twenty four hours after treatments with dimethylsulphoxide (DMSO), PP1, PP2 and PP3 at 10 mM and 30 mM, cells were washed with phosphate-buffered saline (PBS) and resuspended in 10 mM Hepes (pH 7,4), 140 mM NaCl, 2,5 mM CaCl2. Cells were then labelled with AnnexinV-FITC, PI-PE and the percentage of AnnexinV þ , PI þ (apoptotic cells) cells was next determined by flow cytometry (EPICS Elite Cytometer, Beckman Coulter).
Western blotting and immunoprecipitation studies
Immunoprecipitation studies using NP40 cell lysates were performed as previously described (Rosa Santos et al., 2000) . 
